NCT05152680View on ClinicalTrials.gov

Mass Balance Study of NV-5138 in Healthy Male Subjects.

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

November 11, 2021

Primary Completion Date

December 9, 2021

Study Completion Date

December 9, 2021

Conditions
Healthy Volunteers
Interventions
DRUG

[14C]-NV-5138

Single dose, given as oral solution, 1600 mg

Trial Locations (1)

NG116JS

Quotient Sciences, Ruddington

Sponsors
All Listed Sponsors
collaborator

Supernus Pharmaceuticals, Inc.

INDUSTRY

lead

Navitor Pharmaceuticals, Inc.

INDUSTRY